SCHEMBL15375490

SCHEMBL15375490

CCNC(=O)C(OCC)c1ccccc1COc1ccccc1C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.41
FFAR1 O14842 3/20 0.40
RXRA P19793 1/20 0.40
RXRB P28702 1/20 0.40
RXRG P48443 1/20 0.40
NPSR1 Q6W5P4 2/20 0.39
THRB P10828 1/20 0.39
GAA P10253 1/20 0.39
MAPT P10636 1/20 0.39
PKM P14618 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
LMNA P02545 1/20 0.39
PTGDR2 Q9Y5Y4 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.38
PSEN1 P49768 1/20 0.38
PSEN2 P49810 1/20 0.38
APH1B Q8WW43 1/20 0.38
NCSTN Q92542 1/20 0.38
APH1A Q96BI3 1/20 0.38
PSENEN Q9NZ42 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15375646 0.89 LMNA (0.42) MAPTLMNAPTGDR2SMN1; SMN2KDM4E
SCHEMBL15401618 0.83 PTGDR2 (0.45) TDP1RXRARXRBRXRGNPSR1
SCHEMBL15375535 0.81 TSHR (0.41) TDP1RXRARXRBRXRGNPSR1
SCHEMBL7524475 0.79 SMN1; SMN2 (0.44) TDP1GAAPKMLMNAPTGDR2
SCHEMBL2236821 0.77 FABP4 (0.46) TDP1RXRARXRBRXRGNPSR1
SCHEMBL1539445 0.77 TDP1 (0.40) TDP1FFAR1RXRARXRBRXRG
SCHEMBL8305675 0.76 TDP1 (0.47) TDP1RXRARXRBRXRGNPSR1
SCHEMBL8014177 0.76 RXRA (0.51) TDP1RXRARXRBRXRGNPSR1
SCHEMBL15375537 0.75 TDP1 (0.52) TDP1RXRARXRBRXRGNPSR1
SCHEMBL8897564 0.75 FABP4 (0.61) TDP1RXRARXRBRXRGNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2682382-B1 Method for Producing Phenylacetamide Compound SUMITOMO CHEMICAL CO (JP) 2016-11-23 EP disclosed
EP-2662352-B1 Method for Producing Phenylacetamide Compound SUMITOMO CHEMICAL CO (JP) 2016-11-09 EP disclosed
EP-2397459-B1 METHOD FOR PRODUCING PHENYLACETAMIDE COMPOUND SUMITOMO CHEMICAL CO (JP) 2015-12-16 EP disclosed
EP-2682382-A2 Method for Producing Phenylacetamide Compound Sumitomo Chemical Company, Limited (JP) 2014-01-08 EP disclosed
US-8624062-B2 Method for producing phenylacetamide compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2014-01-07 US disclosed
EP-2662352-A2 Method for Producing Phenylacetamide Compound Sumitomo Chemical Company, Limited (JP) 2013-11-13 EP disclosed
EP-2397459-A1 METHOD FOR PRODUCING PHENYLACETAMIDE COMPOUND Sumitomo Chemical Company, Limited (JP) 2011-12-21 EP disclosed
US-20110295035-A1 METHOD FOR PRODUCING PHENYLACETAMIDE COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-12-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110295035-A1 METHOD FOR PRODUCING PHENYLACETAMIDE COMPOUND MRPL21, AADAC, ARSA TDP1 4654/4885FFAR1 3308/4885RXRA 1438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.